Predictors of mortality among multidrug-resistant tuberculosis patients in central Ethiopia: a retrospective follow-up study
暂无分享,去创建一个
[1] G. Sotgiu,et al. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres , 2019, BMC Infectious Diseases.
[2] K. Tamirat,et al. Treatment delay and associated factors among adults with drug resistant tuberculosis at treatment initiating centers in the Amhara regional state, Ethiopia , 2019, BMC Infectious Diseases.
[3] Y. Limenih,et al. Survival analysis of time to cure on multi-drug resistance tuberculosis patients in Amhara region, Ethiopia , 2019, BMC Public Health.
[4] U. Sack,et al. Current treatment of multidrug resistant tuberculosis in Ethiopia: an aggregated and individual patients’ data analysis for outcome and effectiveness of the current regimens , 2018, BMC Infectious Diseases.
[5] T. Holtz,et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis , 2018, The Lancet.
[6] L. Kuonza,et al. Risk factors for mortality among adults registered on the routine drug resistant tuberculosis reporting database in the Eastern Cape Province, South Africa, 2011 to 2013 , 2018, PloS one.
[7] M. Oo,et al. Patients with MDR-TB on domiciliary care in programmatic settings in Myanmar: Effect of a support package on preventing early deaths , 2017, PloS one.
[8] R. Garfein,et al. Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] S. Swaminathan,et al. Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. , 2017, Public health action.
[10] H. Alsdurf,et al. Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade. , 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[11] Tadele Girum,et al. Survival Status and Treatment Outcome of Multidrug Resistant Tuberculosis (MDR-TB) among Patients Treated in Treatment Initiation Centers (TIC) in South Ethiopia: A Retrospective Cohort Study , 2017 .
[12] D. Evans,et al. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study , 2016, BMC Infectious Diseases.
[13] C. Contreras,et al. Baseline Predictors of Treatment Outcomes in Children With Multidrug-Resistant Tuberculosis: A Retrospective Cohort Study. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] Chong-Jen Yu,et al. Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis , 2016, Antimicrobial Agents and Chemotherapy.
[15] L. Fiebig,et al. Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference? , 2016, Thorax.
[16] W. Sha,et al. Efficacy and effect of free treatment on multidrug-resistant tuberculosis , 2015, Experimental and therapeutic medicine.
[17] J. Andrews,et al. Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia—an observational cohort study , 2015, Thorax.
[18] A. Javaid,et al. Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[19] Christopher Gilpin,et al. WHO's new End TB Strategy , 2015, The Lancet.
[20] E. Houpt,et al. Outcomes and Use of Therapeutic Drug Monitoring in Multidrug-Resistant Tuberculosis Patients Treated in Virginia, 2009-2014 , 2015, Tuberculosis and respiratory diseases.
[21] K. Floyd,et al. Multidrug-resistant tuberculosis around the world: what progress has been made? , 2014, European Respiratory Journal.
[22] Sonya S. Shin,et al. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] Shouyong Tan,et al. Risk Factors for Poor Treatment Outcomes in Patients with MDR-TB and XDR-TB in China: Retrospective Multi-Center Investigation , 2013, PloS one.
[24] N. Engel. The making of a public health problem: multi-drug resistant tuberculosis in India. , 2013, Health policy and planning.
[25] A. Scheen,et al. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. , 2013, Diabetes & metabolism.
[26] K. Floyd,et al. Global Epidemiology of Tuberculosis , 2013, Seminars in Respiratory and Critical Care Medicine.
[27] M. Jiménez-Corona,et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes , 2012, Thorax.
[28] K. Fielding,et al. Association of BMI Category Change with TB Treatment Mortality in HIV-Positive Smear-Negative and Extrapulmonary TB Patients in Myanmar and Zimbabwe , 2012, PloS one.
[29] M. Casals,et al. Predictors of Death among Patients Who Completed Tuberculosis Treatment: A Population-Based Cohort Study , 2011, PloS one.
[30] J. Fitzgerald,et al. Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis , 2009, PloS one.
[31] J. Ollgren,et al. Risk factors for poor tuberculosis treatment outcome in Finland: a cohort study , 2007, BMC public health.
[32] L. P. Ormerod. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. , 2005, British medical bulletin.
[33] Y. Amdekar,et al. Multidrug resistant tuberculosis. , 1998, Indian pediatrics.